Questions raised over clinical value of Sanofi's semuloparin ahead of US FDA committee meeting
04:20 EDT 19 Jun 2012 | SCRIP
The staff of the US FDA has presented an extremely negative view of the bid by Sanofi-Aventis to market the experimental blood clot preventative semuloparin sodium. In briefing papers prepared for the 20 June meeting where the agency's independent...
Original Article: Questions raised over clinical value of Sanofi's semuloparin ahead of US FDA committee meeting
More From BioPortfolio on "Questions raised over clinical value of Sanofi's semuloparin ahead of US FDA committee meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
